Abstract 885P
Background
This study aimed to investigate the feasibility of using ligand-targeted polymerase chain reaction (LT-PCR) to detect folate receptor-positive circulating tumor cells (FR+CTCs) and their potential role as an auxiliary marker for diagnosis and treatment monitoring in nasopharyngeal carcinoma (NPC).
Methods
This was a single-center, prospective, non-interventional clinical study at Fujian Cancer Hospital. The study included newly diagnosed nasopharyngeal carcinoma patients with at least one measurable lesion and a benign control group. Patients underwent comprehensive treatment based on radical radiotherapy, and the level of FR+CTC was dynamically detected after treatment. FR+CTC was quantitated using ligand-targeted PCR and verified using immunofluorescence. The ROC curve was used to determine specificity and sensitivity thresholds, and the AUC was calculated. Comparisons between groups were performed using statistical tests, and p < 0.05 was considered statistically significant.
Results
A total of 254 subjects were included in the study, including 145 newly diagnosed NPC patients and 109 healthy volunteers. The study found that the level of FR+CTC was significantly higher in NPC patients than in healthy individuals, and the levels were also higher in stage III and IV patients. The FR+CTC detection method had a higher AUC, and the cut-off value between the NPC and control groups was 9.380 FU/3ml, with a sensitivity of 99.1% and a specificity of 79.2%. The study also found that FR+CTC levels were associated with gender, age, TNM stage, and MPTD, but not with the level of EB-DNA. After radiotherapy, most patients showed a significant decrease in FR+CTC levels, indicating the potential of FR+CTC as a dynamic biomarker for monitoring treatment response in NPC.
Conclusions
This study demonstrates that LT-PCR technology can accurately detect FR+CTCs in NPC patients. FR+CTC has the potential to be used not only as an auxiliary biomarker for early detection and diagnosis of nasopharyngeal carcinoma, but also as a potential marker for dynamic assessment and monitoring of disease progression, recurrence, and metastasis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
900P - COVID-19 in patients with head and neck cancers (HERODOTUS): An international, registry-based, cohort study
Presenter: Amanda Psyrri
Session: Poster session 12
901P - Gut microbiome metagenomics and toxicity outcomes from chemoradiation therapy in head and neck squamous cell carcinoma
Presenter: Antoine Desilets
Session: Poster session 12
902P - Cisplatin-induced ototoxicity in head and neck cancer: The patterns and prediction
Presenter: Chiaki Suzuki
Session: Poster session 12
903P - AL101 therapy in patients with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC): Final ACCURACY trial results and meta-analysis of clinical outcomes
Presenter: Renata Ferrarotto
Session: Poster session 12
904P - Retrospective analysis of adjuvant systemic anti-hormonal therapy for resected androgen receptor-positive (AR+) salivary duct carcinoma (SDC)
Presenter: Jetty Weijers
Session: Poster session 12
905P - Hot topics in salivary gland carcinomas treatment: An EORTC young investigator and early career investigator survey
Presenter: Luigi Lorini
Session: Poster session 12
906P - Multi-parameter flow cytometry analysis of circulating immune cell populations in recurrent/metastatic adenoid cystic carcinoma
Presenter: Samuel Rack
Session: Poster session 12
907P - Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II
Presenter: Laura Locati
Session: Poster session 12
908P - Efficacy of NOTCH inhibitors (Ni) relative to prior systemic therapy or observation in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC)
Presenter: Camilla Hoff
Session: Poster session 12
909P - TROP2 expression in salivary gland adenoid cystic carcinoma (ACC): A new potential therapeutic target for the non-solid subtype
Presenter: Juliana Mota Siqueira
Session: Poster session 12